Citations 2
Prognostic significance of coronary flow velocity reserve in patients with peripheral arterial disease
Cerracchio, Emma, Cortigiani, L, Tuttolomondo, Domenico , Navacchi, Rebecca , Bovenzi, F, Picano, Eugenio , Gaibazzi, Nicola , Ciampi, Quirino , Carerj, Scipione , Pepi, Mauro , Pellikka, Patricia A.
European Heart Journal | October 28, 2024 | Volume: 45 | Issue: Supplement_1 | Pages: No page available
Abstract Background Patients with lower extremity peripheral arterial disease (PAD) have a higher risk of cardiovascular events. Stress echocardiography (SE) based on regional wall motion abnormality (RWMA) is imperfect for risk stratification in PAD, but it can be complemented with an assessment of coronary flow velocity reserve (CFVR) in the mid-distal left anterior descending coronary artery. Purpose To assess the value of SE with RWMA and CFVR to predict survival in PAD. Methods In a retrospective analysis of prospectively acquired data in an observational, multicenter study, we recruited 359 patients (age 69±8 years, 240 [67%] males) with PAD referred for dipyridamole SE in 3 accredited laboratories. We assessed RWMA and CFVR (abnormal value <2.0). All patients were followed up for a median of 4.7 (interquartile range: 2.0 to 8.2 years). All-cause death was the outcome end-point. Results The positivity rate was 37/359 (10%) for RWMA and 159/359 (44%) for CFVR. During follow-up, 97 (27%) deaths were registered. At multivariable analysis, inducible RWMA and/or CFVR <2.0 (HR 2.58, 95% CI 1.65-4.04; p<0.0001), age ≥70 years, diabetes, dialysis treatment, and ejection fraction ≤50% were associated with decreased survival. The annual mortality was 7.4% in patients with RWMA and/or CFVR <2.0 and 2.7% in those with no RWMA and CFVR >2.0 (Figure, p<0.0001). Conclusion In patients with PAD, SE shows more than 4-fold higher prevalence of abnormal CFVR compared to RWMA. The prognostic value of CFVR outperforms RWMA, showing the importance of coronary microvascular dysfunction and diffuse, subcritical coronary atherosclerosis in determining the outcome.
Stress Echo 2030: The Novel ABCDE-(FGLPR) Protocol to Define the Future of Imaging
Pepi, Mauro , Ciampi, Quirino , Cortigiani, Lauro , Arruda‐Olson, Adelaide M. , Daros, Clarissa Borguezan , Pretto, José Luis de Castro e Silva , Bossone, Eduardo , Merli, Elisa , Kane, Garvan C. , Scali, Maria Chiara, Morrone, Doralisa , Simova, Iana , Samardjieva, Martina, Boshchenko, A , Ryabova, T. R. , Pálinkás, Eszter Dalma , Sepp, Róbert , Torres, Marco Antônio Rodrigues , Villarraga, Hector R. , Kovačević-Preradović, Tamara , Citro, Rodolfo , Amor, Miguel , Mosto, Hugo , Salamè, Michael, Leeson, Paul , Gaibazzi, Nicola , Tuttolomondo, Domenico , Prota, Costantina , Peteiro, Jesús , Heyning, Caroline M. Van De , D’Andrea, Antonello , Rigo, Fausto , Ostojić, Miodrag , Arbucci, Rosina , Haber, Diego M. Lowenstein, Merlo, Pablo , Wierzbowska‐Drabik, Karina , Kasprzak, Jarosław D. , Haberka, Maciej , Ratanasit, Nithima , Mori, Fabio , D’Alfonso, Maria Grazia , Tassetti, Luigi , Milazzo, Alessandra , Olivotto, Iacopo , Marchi, Alberto, Rodríguez‐Zanella, Hugo , Zagatina, A , Padang, Ratnasari , Dekleva, Milica , Djordievic-Dikic, Ana, Boskovic, N , Tešić, Milorad , Giga, Vojislav , Salvo, Giovanni Di , Lorenzoni, Valentina , Cameli, Matteo , Bombardini, Tonino, Caso, Pio, Čelutkienė, Jelena , Barbieri, Andréa , Benfari, Giovanni , Bartolacelli, Ylenia , Malagoli, Alessandro , Mantovani, Francesca , Villari, Bruno, Russo, Antonello , Nes, Michele De, Carpeggiani, Clara , Monte, Ines , Re, Federica , Cotrim, Carlos , Bilardo, G, Karužas, Arnas , Matuliauskas, D, Colonna, Paolo , Antonini‐Canterin, Francesco, Pellikka, Patricia A. , (SIECVI), The Stress Echo 2030 Study Group of the Italian Society of Echocardiography and Cardiovascular Imaging, Borguezan-Daros, Clarissa , de Castro E Silva Pretto, José Luis , Bossone, Eduardo , Morrone, Doralisa , Palinkas, Eszter Dalma , Preradović, Tamara Kovačević , Tuttolomondo, Domenico , Peteiro, Jesus , Van De Heyning, Caroline M , D'Andrea, Antonello , Arbucci, Rosina , Wierzbowska-Drabik, Karina , Tassetti, Luigi , Olivotto, Iacopo , Rodriguez-Zanella, Hugo , Tesic, Milorad , Di Salvo, Giovanni , Cameli, Matteo , Mandoli, Giulia Elena , Barbieri, Andrea , Benfari, Giovanni , Bartolacelli, Ylenia , Malagoli, Alessandro , Mantovani, Francesca , Monte, Ines , Cotrim, Carlos , Karuzas, Arnas , Colonna, Paolo , Pepi, Mauro , Pellikka, Patricia A , Ciampi, Quirino , Zagatina, Angela , Kasprzak, Jaroslaw D , Ryabova, Tamara , Gaibazzi, Nicola , Lorenzoni, Valentina , Citro, Rodolfo , Boshchenko, Alla , Celutkiene, Jelena , Cocchia, Rosangela , Varga, Albert , Ágoston, Gergely , Vrublevsky, A. V. , Pálinkás, Attila , Mangia, Cristina , Nikolic, Aleksandra, Lowenstein, Jorge , Camarozano, Ana Cristina , Marchi, Alberto, Beleslin, Branko , Bursi, Francesca , Saad, Ariel K. , (SIECVI), The Stress Echo 2030 Study Group of the Italian Society of Echocardiography and Cardiovascular Imaging
Journal of Clinical Medicine | August 17, 2021 | Volume: 10 | Issue: 16 | Pages: 3641
With stress echo (SE) 2020 study, a new standard of practice in stress imaging was developed and disseminated: the ABCDE protocol for functional testing within and beyond CAD. ABCDE protocol was the fruit of SE 2020, and is the seed of SE 2030, which is articulated in 12 projects: 1-SE in coronary artery disease (SECAD); 2-SE in diastolic heart failure (SEDIA); 3-SE in hypertrophic cardiomyopathy (SEHCA); 4-SE post-chest radiotherapy and chemotherapy (SERA); 5-Artificial intelligence SE evaluation (AI-SEE); 6-Environmental stress echocardiography and air pollution (ESTER); 7-SE in repaired Tetralogy of Fallot (SETOF); 8-SE in post-COVID-19 (SECOV); 9: Recovery by stress echo of conventionally unfit donor good hearts (RESURGE); 10-SE for mitral ischemic regurgitation (SEMIR); 11-SE in valvular heart disease (SEVA); 12-SE for coronary vasospasm (SESPASM). The study aims to recruit in the next 5 years (2021–2025) ≥10,000 patients followed for ≥5 years (up to 2030) from ≥20 quality-controlled laboratories from ≥10 countries. In this COVID-19 era of sustainable health care delivery, SE2030 will provide the evidence to finally recommend SE as the optimal and versatile imaging modality for functional testing anywhere, any time, and in any patient.